NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
21 trialsNCT03595124 2025-12-03
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT02639182 2024-11-18
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Phase 2 Completed
NCT02667886 2024-10-03
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
X4 Pharmaceuticals
Phase 1/2 Completed
NCT05012865 2023-12-06
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Pfizer
Completed
NCT02579811 2023-06-29
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT02133742 2021-07-28
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Pfizer
Phase 1 Completed
NCT03494816 2021-06-30
NAXIVA
Scottish Clinical Trials Research Unit
Phase 2 Completed
NCT01806064 2020-10-19
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Terminated
NCT01599754 2019-09-20
ATLAS
SFJ Pharmaceuticals, Inc.
Phase 3 Terminated
NCT00569946 2019-06-05
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
Pfizer
Phase 2 Completed
NCT01441414 2019-01-08
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Pfizer
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00835978 2017-05-30
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Pfizer
Phase 2 Completed
NCT00282048 2012-07-31
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Pfizer
Phase 2 Completed
NCT01056263 2012-04-20
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
Pfizer
Completed